Heart surgery bleeding study tests best drug dose

NCT ID NCT07164300

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares three different doses of the drug tranexamic acid in 150 adults having elective heart surgery with a heart-lung machine. The goal is to find which dose best controls bleeding and reduces the need for blood transfusions. Researchers will measure how long the drug works and its levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tranexamic acid

What this could lead to

If successful, this study could help doctors choose the best dose of tranexamic acid to reduce bleeding and transfusions during heart surgery.

What could go wrong

This is a small, early-phase trial with 150 participants. Different doses may not show clear benefits, and individual patient responses can vary.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVERSE DRUG EVENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blood coagulation disease Drug-Related Side Effects and Adverse Reactions Hemorrhage Postoperative Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospital of Ioannina

    RECRUITING

    Ioannina, Greece

    Contact Phone: •••-•••-•••• Email: •••••@•••••